STOCK TITAN

Minerva Neurosciences Inc - NERV STOCK NEWS

Welcome to our dedicated news page for Minerva Neurosciences (Ticker: NERV), a resource for investors and traders seeking the latest updates and insights on Minerva Neurosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Minerva Neurosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Minerva Neurosciences's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.15%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.85%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.52%
Tags
conferences earnings
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
47.83%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.89%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
Minerva Neurosciences Inc

Nasdaq:NERV

NERV Rankings

NERV Stock Data

17.48M
5.44M
22.26%
35.1%
0.58%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Waltham

About NERV

minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its